Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).

Abstract:

:Expression of epidermal growth factor and its transmembrane receptor (EGFR) stimulates tumor growth. Matuzumab is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth, and provides a clinical benefit for some patients. The plasma half-life (6-10 days) and pharmacodynamic activity allow flexible dosing on weekly, every-2-week, and every-3-week schedules. Matuzumab has shown single-agent antitumor activity in heavily pretreated patients with a variety of tumors, with a favorable safety profile. Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab.

journal_name

Cancer Invest

journal_title

Cancer investigation

authors

Schiller JH

doi

10.1080/07357900701511847

subject

Has Abstract

pub_date

2008-02-01 00:00:00

pages

81-95

issue

1

eissn

0735-7907

issn

1532-4192

pii

788760697

journal_volume

26

pub_type

杂志文章,评审
  • Phase II trial of paclitaxel in patients with soft-tissue sarcoma.

    abstract::The response rate (RR) to single-agent chemotherapy with doxorubicin or ifosfamide in patients with advanced soft-tissue sarcoma (STS) is in the range of 20%. Paclitaxel is clinically useful in treating several solid tumors and has demonstrated activity in a series of human sarcoma cell lines. Twenty-eight patients wi...

    journal_title:Cancer investigation

    pub_type: 临床试验,杂志文章

    doi:10.3109/07357909809011697

    authors: Casper ES,Waltzman RJ,Schwartz GK,Sugarman A,Pfister D,Ilson D,Woodruff J,Leung D,Bertino JR

    更新日期:1998-01-01 00:00:00

  • Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS).

    abstract:BACKGROUND:Rapid and efficient symptom assessment is an important aspect of palliative care. The objective was to determine whether a smaller number of symptoms from the 32-item Memorial Symptom Assessment Scale Short-Form (MSAS-SF) could convey equivalent quality of life (QOL) information. METHODS:Responses from 479 ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1081/cnv-200026487

    authors: Chang VT,Hwang SS,Kasimis B,Thaler HT

    更新日期:2004-01-01 00:00:00

  • CD147 impacts angiogenesis and metastasis formation.

    abstract::CD147 is highly expressed on many tumor cells; its role for tumor invasiveness and metastasis has been deduced from its capacity to induce MMPs, i.e., MMP-1, -2, -3, and -9. However, in the murine B16 melanoma model, MMP-2/-9 expression occurs independent of CD147. To scrutinize the impact of CD147 on metastasis forma...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1080/07357900802392675

    authors: Voigt H,Vetter-Kauczok CS,Schrama D,Hofmann UB,Becker JC,Houben R

    更新日期:2009-03-01 00:00:00

  • Mitochondrial DNA alterations in cancer.

    abstract::A number of studies have demonstrated the presence of mitochondrial DNA (mtDNA) mutations in cancer cells. In this article, we review mitochondrial genomic aberrations reported in solid tumors of the breast, colon, stomach, liver, kidney, bladder, head/neck, and lung. The tantalizing association of tumors with mtDNA m...

    journal_title:Cancer investigation

    pub_type: 杂志文章,评审

    doi:10.1081/cnv-120002155

    authors: Copeland WC,Wachsman JT,Johnson FM,Penta JS

    更新日期:2002-01-01 00:00:00

  • Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.

    abstract::Platelet-derived growth factor D (PDGF-D) has been shown to mediate cellular processes of importance in cancer progression. This study aimed to investigate the expression and putative involvement of PDGF-D signaling in colorectal carcinogenesis. PDGF-D was expressed in vascular endothelial cells in tumor and normal ti...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1080/07357907.2019.1576191

    authors: Olsen RS,Dimberg J,Geffers R,Wågsäter D

    更新日期:2019-01-01 00:00:00

  • Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole.

    abstract::Mucositis is a common and often serious acute morbidity when radiation is delivered to portals encompassing the oral cavity, pharynx, or esophagus. In an effort to minimize this side effect, the combination of sucralfate and fluconazole was prescribed to 40 patients. Half were given sucralfate, 1 g in suspension q.i.d...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357909509024890

    authors: Allison RR,Vongtama V,Vaughan J,Shin KH

    更新日期:1995-01-01 00:00:00

  • Alpha-fetoprotein synthesis in human hepatocellular carcinoma: correlation with hepatitis B surface antigen expression.

    abstract::We analyzed the pattern of alpha-fetoprotein (AFP) synthesis in 40 consecutive human hepatocarcinomas (HCC) in relation to hepatitis B viral (HBV) infection. In addition, histopathological characteristics of liver parenchyma and the tumor itself were examined. Elevated AFP (> 20 ng/ml) were found in 90% of HCC patient...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357909209024813

    authors: Kashala LO,Kalengayi MM,Essex M

    更新日期:1992-01-01 00:00:00

  • Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

    abstract:OBJECTIVES:To evaluate the efficacy and toxicity of the combination of vinorelbine and interleukin (IL)-2 in patients with metastatic melanoma as second-line chemotherapy. PATIENTS AND METHODS:Twenty-two patients with histologically confirmed stage IV melanoma previously treated with temozolomide-based chemotherapy--o...

    journal_title:Cancer investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1081/cnv-200039630

    authors: Gogas H,Bafaloukos D,Aravantinos G,Fountzilas G,Tsoutsos D,Panagiotou P,Frangia K,Kalofonos HP,Briasoulis E,Castana O,Polyzos A,Pectasides D,Ioannovich J,Hellenic Cooperative Oncology Group.

    更新日期:2004-01-01 00:00:00

  • Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids.

    abstract::Targeting the nuclear factor kappa B (NFκB) pathway is proposed as therapy for chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) supplement would suppress NFκB activation in lymphocytes of Rai Stage 0-1 CLL patients. The initial dose of 2.4 g n-3/day was gradually increased to 7.2 g...

    journal_title:Cancer investigation

    pub_type: 临床试验,杂志文章

    doi:10.3109/07357907.2012.743553

    authors: Fahrmann JF,Ballester OF,Ballester G,Witte TR,Salazar AJ,Kordusky B,Cowen KG,Ion G,Primerano DA,Boskovic G,Denvir J,Hardman WE

    更新日期:2013-01-01 00:00:00

  • A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.

    abstract::PS-341, now known as bortezomib (Velcade[Millenium Pharmaceuticals, Inc., Cambridge, MA; and Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring house, PA]), is a proteasome inhibitor approved for the treatment of refractory multiple myeloma. Preclinical and early clinical studies showed PS-341 to be ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1080/07357900701506573

    authors: Engel RH,Brown JA,Von Roenn JH,O'Regan RM,Bergan R,Badve S,Rademaker A,Gradishar WJ

    更新日期:2007-12-01 00:00:00

  • In vivo and in vitro antitumor effects of a staphylococcal enterotoxin A mutant (SEA-H61D).

    abstract::In this study, we evaluated SEA-H61D, a staphylococcal enterotoxin A mutant without emetic activity, as an antitumor agent in vitro and in vivo. It showed that SEA-H61D could significantly inhibit the growth of many cancer cell lines in vitro at very low concentrations by activating human peripheral blood mononuclear ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357900903286982

    authors: Wang HR,Jiang H,Hao HJ,Zheng YL,Jie KG,Gu J,Jiang YQ

    更新日期:2010-10-01 00:00:00

  • Immunoregulation of murine plasmacytoma. II. Target selectivity of anomalous killer cells and role of immune T cells for the induction.

    abstract::Requirements for the induction of anomalous killer (AK) cells to syngeneic MOPC 104E-KI81 plasmacytoma, and their pattern of reaction were investigated. The AK cells are Thy-1.2 positive and were induced by cocultivation of normal BALB/c spleen cells for 5 days in vitro with mitomycin C-treated MOPC 104E-KI81 cells in...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357908909038265

    authors: Hayashida I,Hiramoto RN,Shrestha K,Ghanta VK

    更新日期:1989-01-01 00:00:00

  • Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?

    abstract::For women with hormone receptor-positive disease, the third-generation aromatase inhibitors (AIs), anastrozole, letrozole, and exemestane, are more effective than tamoxifen in improving disease-free survival (DFS) when used initially or as adjuvant therapy following two to three years of tamoxifen or after tamoxifen h...

    journal_title:Cancer investigation

    pub_type: 杂志文章,评审

    doi:10.1080/07357900701781812

    authors: Tang SC

    更新日期:2008-06-01 00:00:00

  • Polymorphic AAAG repeat length in estrogen-related receptor gamma (ERRγ) and risk of breast cancer in Iranian women.

    abstract::Estrogen-related receptors (ERRs) alpha, beta, and gamma are orphan nuclear receptors that modulate the estrogen signaling pathway and play roles in the regulation of breast cancer cell growth. To determine the association between breast cancer risk and alleles of the tetranucleotide repeat (AAAG)n in the intron of ER...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357907.2013.845672

    authors: Karimi P,Hematti S,Safari F,Tavassoli M

    更新日期:2013-11-01 00:00:00

  • Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin RNA targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells.

    abstract::It is believed that telomerase is a terminal effector and its role is to maintain the length of telomeres. However, the main rate-limiting subunit of telomerase, human telomerase reverse transcriptase (hTERT), has been recently proved to have the ability to affect a variety of other genes such as p53 independently of ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357900802491451

    authors: Luo Y,Yi Y,Yao Z

    更新日期:2009-12-01 00:00:00

  • Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.

    abstract::A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and outcome of immune checkpoint inhibitors (ICI). The pooled hazard ratio (HR) suggested elevated pretreatment NLR was associated with poor OS (HR:...

    journal_title:Cancer investigation

    pub_type: 杂志文章,meta分析

    doi:10.1080/07357907.2019.1639057

    authors: Xie X,Liu J,Yang H,Chen H,Zhou S,Lin H,Liao Z,Ding Y,Ling L,Wang X

    更新日期:2019-01-01 00:00:00

  • Expression of Circadian Clock Genes in Human Colorectal Cancer Tissues Using Droplet Digital PCR.

    abstract::Increasing evidence indicates that disruption of circadian rhythms may be directly linked to cancer. Here we report that the expression levels of the core clock genes Per1 and Per3 measured by droplet digital polymerase chain reaction are significantly decreased in tumour tissue from 16 patients undergoing colorectal ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1080/07357907.2019.1571079

    authors: Orhan T,Nielsen PB,Hviid TVF,Rosen AW,Gögenür I

    更新日期:2019-01-01 00:00:00

  • Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer.

    abstract::Between March 1986 and December 1987, two groups of consecutive patients with advanced breast cancer underwent epidoxorubicin (Epidx) monochemotherapy. Twenty-three patients (group A) received Epidx at a dose of 60 mg/m2 and 27 (group B) at a dose of 120 mg/m2 (i.v. every 3 weeks). No patient had undergone anthracycli...

    journal_title:Cancer investigation

    pub_type: 临床试验,杂志文章

    doi:10.3109/07357909309024827

    authors: Neri B,Pacini P,Algeri R,Lottini G,Rinaldini M,Tucci E,Pusterla R

    更新日期:1993-01-01 00:00:00

  • Anti-angiogenic treatment of gastrointestinal malignancies.

    abstract::The scientific rationale to block angiogenesis as a treatment strategy for human cancer has been developed over the last 30 years, but is only now entering the clinical arena. Preclinical studies have demonstrated the importance of the vascular endothelial growth factor (VEGF) pathways in both physiologic and patholog...

    journal_title:Cancer investigation

    pub_type: 杂志文章,评审

    doi:10.1080/07357900500360024

    authors: Salmon JS,Lockhart AC,Berlin J

    更新日期:2005-01-01 00:00:00

  • Case-control study of breast cancer in India: Role of PERIOD3 clock gene length polymorphism and chronotype.

    abstract:BACKGROUND:This study examined a PERIOD3 (PER3) gene variable number tandem repeat polymorphism and chronotype as potential BrCA risk factors among Indian women. METHODS:This case-control study included sporadic, histologically confirmed BrCA cases (n = 255) and controls (n = 249) from India with data collection from ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357907.2014.919305

    authors: Wirth MD,Burch JB,Hébert JR,Kowtal P,Mehrotra-Kapoor A,Steck SE,Hurley TG,Gupta PC,Pednekar MS,Youngstedt SD,Zhang H,Sarin R

    更新日期:2014-08-01 00:00:00

  • Phase I-II trial of high-dose melphalan in previously untreated stage III multiple myeloma: Cancer and Leukemia Group B study 8512.

    abstract::To study the efficiency of high-dose melphalan in previously untreated patients with advanced myeloma, we performed a Phase I-II trial. Twenty-eight patients were treated at dose level of 60-140 mg/m2. Each patient was first treated with a priming dose of cyclophosphamide (300 mg) followed by high-dose melphalen 1 wee...

    journal_title:Cancer investigation

    pub_type: 临床试验,杂志文章

    doi:10.3109/07357909209032784

    authors: Case DC Jr,Coleman M,Gottlieb A,McCarroll K

    更新日期:1992-01-01 00:00:00

  • MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer.

    abstract::In this study, we investigated ALDH1A3, Mcl1, and miR-125a/b expression in HT29 cells and the effect of miR-125a/b on ALDH1A3 and Mcl1 expression. Our results showed that low expression of miR-125a/b and high expression of ALDH1A3 and Mel1 were observed in both ALDH1-positive HT29 and HT29-taxol cells. Overexpression ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357907.2012.743557

    authors: Chen J,Chen Y,Chen Z

    更新日期:2013-01-01 00:00:00

  • Intensity modulated arc therapy in bilaterally irradiated head and neck cancer: a comparative and prospective multicenter planning study.

    abstract::A dosimetric comparison was made of Helical Tomotherapy (HT) and Rapid'Arc(®) (RA) in 115 patients with head and neck carcinoma included in a prospective and multicentric study. HT and RA provided highly conformal plans that easily complied with dose volume constraints for organs at risk. HT reduced high doses to the ...

    journal_title:Cancer investigation

    pub_type: 杂志文章,多中心研究

    doi:10.3109/07357907.2014.889705

    authors: Vernat SS,Ali D,Messina C,Pommier P,Dussart S,Puyraveau M,Viard R,Lacornerie T,Lisbona A,Fenoglietto P,Mazurier J,Garcia R,Hangard G,Zefkili S,Makovicka L,Giraud P

    更新日期:2014-06-01 00:00:00

  • Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.

    abstract:OBJECTIVE:Patients with systemic malignancies have substantial quantities of tumor-specific DNA in their plasma which may serve as a potential biomarker for tumor burden. This approach has not been studied in gliomas. METHODS:Methylation specific polymerase chain reaction (MSP) was used to determine the methylation st...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1080/07357900500449546

    authors: Weaver KD,Grossman SA,Herman JG

    更新日期:2006-02-01 00:00:00

  • Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.

    abstract::High expression of vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma (HCC) is associated with poor prognosis. Here, we investigated the antitumor activity of lenvatinib, a multiple receptor tyrosine kinase inhibitor, in VEGF-overexpressing HCC models. In human umbilical vein endotheli...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1080/07357907.2019.1601209

    authors: Adachi Y,Matsuki M,Watanabe H,Takase K,Kodama K,Matsui J,Funahashi Y,Nomoto K

    更新日期:2019-01-01 00:00:00

  • The effect of castration on the synthesis and secretion of proteins in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.

    abstract:UNLABELLED:The effect of castration on the incorporation of [35S]methionine into secreted proteins in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors, was investigated. Biopsy specimens were obtained from 19 tumors, 0, 24, 48, 72, and 96 h after castration. In 14 tumors, castration induced an increase ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357909209032762

    authors: Geier A,Hemi R,Beery R,Lunenfeld B

    更新日期:1992-01-01 00:00:00

  • Papilloma and polyoma DNA tumor virus sequences in female genital tumors.

    abstract::Human papillomaviruses (HPVs) and BKV, JCV, and SV40 polyomaviruses (PYVs) are oncogenic viruses associated with different human tumors. Our aim was to determine if PYV and HPV sequences could be detected in human genital tumors. HPV types 6b, 11, 16, and 18 and PYV were investigated in 22 genital tumor samples and th...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.1081/cnv-200032937

    authors: Martini F,Iaccheri L,Martinelli M,Martinello R,Grandi E,Mollica G,Tognon M

    更新日期:2004-01-01 00:00:00

  • Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

    abstract::This study combined infusional mitoxantrone with bolus melphalan as a transplant preparative regimen for multiple myeloma. Mitoxantrone was infused over 6 hr on days 6 and 5. Melphalan was given as a 15 min bolus on day 1 followed by autologous transplant on day 0. Thirty-five patients were enrolled; 57% of enrollees ...

    journal_title:Cancer investigation

    pub_type: 杂志文章

    doi:10.3109/07357907.2010.550663

    authors: Beaven AW,Moore DT,Sharf A,Serody JS,Shea TC,Gabriel DA

    更新日期:2011-03-01 00:00:00

  • Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials.

    abstract::There appears to be exceptional and growing public enthusiasm for botanical, or "herbal", medicines, especially amongst cancer patients. This has recently begun to be matched by increasing scientific attention. Whilst it is known that plant extracts are active against cancer, the standard approach has been to isolate,...

    journal_title:Cancer investigation

    pub_type: 杂志文章,评审

    doi:10.1081/cnv-120005926

    authors: Vickers A

    更新日期:2002-01-01 00:00:00

  • Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma.

    abstract::Two groups of patients with disseminated breast carcinomas who had failed radiotherapy, chemotherapy, and hormonotherapy were treated with natural interferon alpha (nIFN-alpha) alone or in combination with nIFN-gamma delivered in cycles of 10-12 intralesional (i.l.) injections to recurrent and metastatic lesions. In g...

    journal_title:Cancer investigation

    pub_type: 临床试验,杂志文章

    doi:10.3109/07357909509011686

    authors: Habif DV,Ozzello L,De Rosa CM,Cantell K,Lattes R

    更新日期:1995-01-01 00:00:00